Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus plus dalotuzumab versus exemestane or monotherapy in ER-positive advanced breast cancer
2010-019867-13Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ridaforolimus, dalotuzumab and exemestane in breast cancer (4 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Progression-free survival in Ki67-high subgroup. Started Jun 2010; status: completed.
02
Drugs
ridaforolimusdalotuzumabexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-019867-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019867-13.